

REMARKS


This is an amendment and response to the restriction requirement mailed October 3, 2003 for the above-identified application. The Specification has been amended to disclose that this application claims priority to U.S. Provisional Patent Application Ser. No. 60/196698, filed April 13, 2000.

In response to the Examiner's restriction requirement, Applicants elect with traverse the invention defined as Group 7 in the Official Action of October 3, 2003, i.e., the invention claimed in Claims 4, 13, 14, 16, 18-22, 30, 31 and 33. Claims 15 and 17 have been cancelled and their limitations have been included in Claims 4 and 13, in accordance with the definition of Group 7. All other claims have been withdrawn. Applicants reserve the right to prosecute non-elected subject and cancelled subject matter in separate applications. Claims 4, 13, 14, 16, 18-22, 30, 31 and 33 are now pending in the application. Claims 4, 13, and 14 have been amended to comport to the restriction requirement, and Claims 16, 18, 30, 31 and 33 have been amended to change the dependency of the claim in each case. In addition, in response to the Examiner's further restriction requirement, Applicants elect with traverse the species 4-(1-ethylpropoxy)-3,6-dimethyl-2-(2,4,6-trimethylphenoxy)-pyridine as a corticotropin releasing factor antagonist and the species 2-amino-N-(2-(3a-(R)-benzyl-2-methyl-3-oxo-2,3,3a,4,6,7-hexahydropyrazolo-[4,3-c]pyridin-5-yl)-1-(R)-benzyloxymethyl-2-oxo-ethyl)-isobutyramide as a growth hormone secretagogue. Both of the Examiner's restriction requirements are respectfully traversed since it is respectfully submitted that all claims may be properly examined together without undue burden to the Examiner.

In view of the foregoing, examination and allowance of all pending claims is respectfully requested.

The Commissioner is hereby authorized to charge any fees required under 37 C.F.R. §§1.16 and 1.17 or to credit any overpayment to Deposit Account No. 16-1445.

Date: October 16, 2003


Andrea Dorigo
Attorney for Applicant(s)
Reg. No. 47,532

Pfizer Inc
Patent Department
150 East 42nd Street - 5th Floor
New York, NY 10017-5755
(212) 733-1898